1.Khanna D，Fitzgerald JD，Khanna PP，et al.American College of Rheumatology guidelines for management of gout.Part 1：systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia.Arthritis Care Res（Hoboken），2012，64（10）：1431-1446.

2.穆勇昕，王战建．痛风降尿酸药物的疗效评价．药品评价，2014，11（1）：24-27.

3.Marangella M.Uric acid elimination in the urine.Pathophysiological implications.Contrib Nephrol，2005，147：132-148.

4.Unger S，Tausche AK，Kopprasch S，et al.Molecular basis of primary renal hyperuricemia：role of the human urate transporter hURAT1.Z Rheumatol，2007，66（7）：556，558-561.

5.Andreasen F，Jakobsen P，Kornerup HJ，et al.Changes in blood chemistry in hypertensive patients during propranolol therapy.Br J Clin Pharmacol，1984，17（3）：265-271.

6.祝晓雨，赵志刚，韩容．治疗痛风药物非布司他的临床应用与进展．药品评价，2014，11（20）：22-28.

7.郑文洁，唐福林．痛风的治疗进展．中华医学杂志，2002（10）：716-717.

8.王圣燕，赵晶，车仁宇．痛风的药物治疗研究进展．中国医疗前沿，2009，4（9）：42-44.

9.中华医学会内分泌学分会．高尿酸血症和痛风治疗中国专家共识．2013.

10.刘永贵，赵丽嘉，崔艳丽，等．抗高尿酸血症药物研究进展．现代药物与临床，2015，30（3）：345-350.

11.Hanvivadhanakul P，Akkasilpa S，Deesomchok U.Efficacy of benzbromarone compared to allopurinol in lowering serum uric acid level in hyperuricemic patients.J Med Assoc Thai，2002，85 Suppl 1：S40-47.

12.Ogino K，Kato M，Furuse Y，et al.Uric acid-lowering treatment with benzbromarone in patients with heart failure：a double-blind placebo-controlled crossover preliminary study.Circ Heart Fail，2010，3（1）：73-81.

13.Uchida S，Shimada K，Misaka S，et al.Benzbromarone pharmacokinetics and pharmacodynamics in different cytochrome P450 2C9 genotypes.Drug Metab Pharmacokinet，2010，25（6）：605-610.

14.FierceMarkets.AstraZeneca’s，PhⅢ gout data for lesinurad includes a hit，a strikeout and a missing player.2014.Accessed 11-16.

15.plc A.AstraZeneca announces top-line results from the Phase Ⅲ programme of lesinurad in combination with xanthine oxidase inhibitors in gout patients.2014.Accessed 08-13.

16.Nakashima M，Uematsu T，Kosuge K，et al.Pilot study of the uricosuric effect of DuP-753，a new angiotensin Ⅱreceptor antagonist，in healthy subjects.Eur J Clin Pharmacol，1992，42（3）：333-335.

17.Sweet CS，Bradstreet DC，Berman RS，et al.Pharmacodynamic activity of intravenous E-3174，an angiotensin Ⅱantagonist，in patients with essential hypertension.Am J Hypertens，1994，7（12）：1035-1040.

18.Edwards RM，Trizna W，Stack EJ，et al.Interaction of nonpeptide angiotensin Ⅱ receptor antagonists with the urate transporter in rat renal brush-border membranes.J Pharmacol Exp Ther，1996，276（1）：125-129.

19.Johnson RJ，Kang DH，Feig D，et al.Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease？Hypertension，2003，41（6）：1183-1190.

20.Wurzner G，Gerster JC，Chiolero A，et al.Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout.J Hypertens，2001，19（10）：1855-1860.

21.Roychowdhury D，Padhy AK，Tiwari SC，et al.Effects of acute administration of nifedipine on glomerular filtration rate and urinary excretion of sodium and uric acid in patients with mild-moderate essential hypertension.Indian J Physiol Pharmacol，1988，32（4）：278-284.

22.Zawadzki J，Grenda R，Januszewicz P.Effect of nifedipine on tubular handling of uric acid in transplanted kidney on cyclosporine A treatment.Nephron，1995，70（1）：77-82.

23.Ruilope LM，Kirwan BA，de Brouwer S，et al.Uric acid and other renal function parameters in patients with stable angina pectoris participating in the ACTION trial：impact of nifedipine GITS（gastro-intestinal therapeutic system）and relation to outcome.J Hypertens，2007，25（8）：1711-1718.

24.Athyros VG，Mikhailidis DP，Papageorgiou AA，et al.The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease.A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation（GREACE）study.J Clin Pathol，2004，57（7）：728-734.

25.Athyros VG，Elisaf M，Papageorgiou AA，et al.Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease：a subgroup analysis of the GREek Atorvastatin and Coronaryheart-disease Evaluation（GREACE）study.Am J Kidney Dis，2004，43（4）：589-599.

26.Athyros VG，Mikhailidis DP，Liberopoulos EN，et al.Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome：a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation（GREACE）Study.Nephrol Dial Transplant，2007，22（1）：118-127.

27.Caspi D，Lubart E，Graff E，et al.The effect of mini-dose aspirin on renal function and uric acid handling in elderly patients.Arthritis Rheum，2000，43（1）：103-108.

28.Louthrenoo W，Kasitanon N，Wichainun R，et al.Effect of minidose aspirin on renal function and renal uric acid handling in healthy young adults.J Clin Rheumatol，2002，8（6）：299-304.

29.Segal R，Lubart E，Leibovitz A，et al.Renal effects of low dose aspirin in elderly patients.Isr Med Assoc J，2006，8（10）：679-682.

30.程丽静，刘洁，钱叶勇，等．咪唑立宾用于肾移植患者的不良反应观察．药物流行病学杂志，2006，（6）：354-355.

31.明爱民，林民专，赵明，等．咪唑立宾在尸体肾移植术后的应用．临床泌尿外科杂志，2003，18（1）：6-7.

32.郭宏波．咪唑立宾治疗过程中出现的伴发高尿酸血症的急性移植肾功能衰竭2例报告．北京医学，2010，32（11）：945-946.